phosphorylated tau(Thr)181 in serum/plasma (plasma ptau181)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]

Reference interval

Clinical significance

Methods

More general terms

References

  1. ↑ 1.0 1.1 Thijssen EH, La Joie R, Wolf A et al Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine 2020. March 2 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32123386 https://www.nature.com/articles/s41591-020-0762-2
  2. ↑ 2.0 2.1 Palmqvist S, Janelidze S, Quiroz YT et al Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. Published online July 28, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32722745 https://jamanetwork.com/journals/jama/fullarticle/2768841
  3. ↑ Barthelemy NR, Horie K, Sato C Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med (2020) 217 (11): e20200861 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32725127 https://rupress.org/jem/article/217/11/e20200861/151982/Blood-plasma-phosphorylated-tau-isoforms-track-CNS
  4. ↑ Mattsson-Carlgren N et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain 2020 Dec 5; 143:3234. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33068398 Free PMC article https://academic.oup.com/brain/article/143/11/3234/5929275
  5. ↑ 5.0 5.1 George J Alzheimer's Blood Test Predicts Pathology - -tau181: "an important advance that could transform the diagnosis of Alzheimer's disease" MedPage Today January 6, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/90555
    Karikari TK, Pascoal TA, Ashton NJ et al Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts Lancet Neurol. 2020 May;19(5):422-433. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32333900 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30071-5/fulltext
    Karikari TK, Benedet AL, Ashton NJ et al Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol Psychiatry. 2020 Oct 26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33106600
  6. ↑ Janelidze S, Berron D, Smith R et al Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2021;78(2):149-156 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33165506 PMCID: PMC7653537 Free PMC article https://jamanetwork.com/journals/jamaneurology/fullarticle/2772866
  7. ↑ Largent EA, Wexler A, Karlawish J The Future Is P-Tau - Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests. JAMA Neurol. 2021;78(4):379-380 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33393982 https://jamanetwork.com/journals/jamaneurology/fullarticle/2774173
  8. ↑ Pereira JB et al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain 2021 Jun 2; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34077494 https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awab163/6291241
  9. ↑ 9.0 9.1 9.2 George J Blood Test Discerns Alzheimer's From Other Dementia With High Accuracy. Plasma p-tau moves another step closer to clinical use. MedPage Today August 23, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/94177
    Thijssen EH, La Joie R, Strom A et al Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34418401 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00214-3/fulltext
    Parnetti L, Di Filippo M, Gaetani L et al A blood test for Alzheimer's disease: a step forward. Lancet Neurol 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34418386 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00254-4/fulltext
    Thijssen EH, La Joie R, Wolf A et al Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine 2020. March 2 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32123386 https://www.nature.com/articles/s41591-020-0762-2
  10. ↑ Janelidze S, Christian BT, Price J et al Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurol. Published online July 5, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35789365 https://jamanetwork.com/journals/jamaneurology/fullarticle/2793702
  11. ↑ 11.0 11.1 Liang F, Baldyga K, Quan Q et al Preoperative Plasma Tau-PT217 and Tau-PT181 Are Associated With Postoperative Delirium Annals of Surgery. 2022 July 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35794069 https://journals.lww.com/annalsofsurgery/Abstract/9900/Preoperative_Plasma_Tau_PT217_and_Tau_PT181_Are.70.aspx
  12. ↑ 12.0 12.1 Morrison MS et al. Antemortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. Brain 2022 May 13; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35554506 https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awac175/6585495
  13. ↑ George J Blood Test Predicts Which People With Amyloid Are Likely to Decline Cognitively. Plasma p-tau217 outperformed other preclinical Alzheimer's measures. MedPage Today February 6, 2023 https://www.medpagetoday.com/neurology/alzheimersdisease/102970
    Mattsson-Carlgren N, Salvado G, Ashton NJ et al Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. Published online February 6, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36745413 https://jamanetwork.com/journals/jamaneurology/fullarticle/2801289
  14. ↑ 14.0 14.1 Dark HE, Paterson C, Daya GN et al Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk. Ann Neurol. 2023. Oct 6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37801487 https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26817
  15. ↑ 15.0 15.1 George J Alzheimer's Blood Test Predicts Who Might Benefit Most From Anti-Amyloid Drugs. Novel two-cutoff approach may reduce need for confirmatory PET scans. MedPage Today December 5, 2023 https://www.medpagetoday.com/neurology/alzheimersdisease/107691
    Mattsson-Carlgren N, Collij LE, Stomrud E et al Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurol. Published online December 4, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38048096 https://jamanetwork.com/journals/jamaneurology/article-abstract/2812432
  16. ↑ Mielke MM, Dage JL, Frank RD et al Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022 Jul;28(7):1398-1405. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35618838 PMCID: PMC9329262 Free PMC article.
  17. ↑ Ghahremani M, Wang M, Chen HY et al Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. Neurology. 2023 Feb 14;100(7):e683-e693. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36323521 PMCID: PMC9969916 Free PMC article.
  18. ↑ 18.0 18.1 LabPhosphorylated Tau 181 (pTau-181), Plasma CPT: 83520 https://www.labcorp.com/tests/483745/phosphorylated-tau-181-ptau-181-plasma
Retrieved from "https://aaushi.info/w/index.php?title=A492045&oldid=1188620"